candesartan has been researched along with Alloxan Diabetes in 26 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study examines whether the AT1R blocker candesartan (1) has a beneficial effect on diabetes-induced alteration of pressure-induced vasodilation (PIV, a cutaneous physiological neurovascular mechanism which could delay the occurrence of tissue ischemia), and (2) could be protective against skin pressure ulcer formation." | 7.81 | Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice. ( Achard, JM; Bessaguet, F; Danigo, A; Demiot, C; Javellaud, J; Nasser, M; Oudart, N, 2015) |
| "Candesartan treatment (10 or 30 mg/kg; orally) was initiated one day post CLI and thereafter once daily for up to 14 days." | 5.91 | Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway. ( Abdelaziz, RR; Elshaer, SL; Khaled, S; Suddek, GM, 2023) |
| " The present study examines whether the AT1R blocker candesartan (1) has a beneficial effect on diabetes-induced alteration of pressure-induced vasodilation (PIV, a cutaneous physiological neurovascular mechanism which could delay the occurrence of tissue ischemia), and (2) could be protective against skin pressure ulcer formation." | 3.81 | Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice. ( Achard, JM; Bessaguet, F; Danigo, A; Demiot, C; Javellaud, J; Nasser, M; Oudart, N, 2015) |
| "Candesartan reduced CTGF expression and attenuated the fibrosis in diabetic rat atria." | 3.77 | Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling. ( Aizawa, T; Fu, LT; Kaneko, S; Kato, T; Sagara, K; Sekiguchi, A; Takamura, M; Tsuneda, T; Yamashita, T, 2011) |
| "We have identified a novel mechanism by which candesartan improves diabetic retinopathy through the restoration of GLO-I." | 3.76 | Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. ( Binger, KJ; Cooper, ME; Miller, AG; Nagaraj, RH; Pickering, RJ; Tan, G; Thomas, MC; Wilkinson-Berka, JL, 2010) |
| "After diabetes was initiated, candesartan treatment could not reverse the state of diabetes, but it effectively improved glucose tolerance and protected beta-cell function by attenuating oxidative stress, islet fibrosis, sparsity of blood supply and ultrastructure disruption in a dose-dependent and blood pressure-independent manner." | 3.74 | Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice. ( Du, H; Iwashita, N; Kawamori, R; Shao, JQ; Wang, J; Wang, YT; Wang, YY; Watada, H; Zhao, M, 2007) |
| "Time-dependent elevation of MCP-1 expression was dramatically suppressed by treatment with the angiotensin-converting enzyme inhibitor enalapril or the AT1 receptor antagonist candesartan, and was closely associated with effects on proteinuria and glomerular macrophage number." | 3.70 | Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. ( Brenner, BM; Kato, S; Lee, KW; Luyckx, VA; MacKenzie, HS; Ots, M; Troy, JL; Ziai, F, 1999) |
| "Candesartan treatment (10 or 30 mg/kg; orally) was initiated one day post CLI and thereafter once daily for up to 14 days." | 1.91 | Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway. ( Abdelaziz, RR; Elshaer, SL; Khaled, S; Suddek, GM, 2023) |
| " There was a marked decrease in nitric oxide (NO) bioavailability and antioxidant enzyme capacity." | 1.40 | Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. ( El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014) |
| "Diabetic nephropathy is a leading cause of end-stage renal disease." | 1.36 | The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. ( Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Giunti, S; Jandeleit-Dahm, KA; Thomas, MC, 2010) |
| "Type 1 diabetes was induced in rats by intraperitoneally injecting spontaneously hypertensive rats with streptozotocin." | 1.35 | Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats. ( Hayashi, K; Iigaya, K; Itoh, H; Kamayachi, T; Kumagai, H; Onami, T; Osaka, M; Sakata, K; Saruta, T; Takimoto, C, 2008) |
| "Hypertension is a leading risk factor for the development and progression of diabetic retinopathy and contributes to a variety of other retinal diseases in the absence of diabetes mellitus." | 1.35 | Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. ( Bursell, SE; Chilcote, TJ; Clermont, AC; Feener, EP; Phipps, JA; Sinha, S, 2009) |
| "In candesartan-treated DM rats, UT-A3 increased in IM tip (160 +/- 14%) and base (210 +/- 19%)." | 1.35 | Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney. ( Blount, MA; Kent, KJ; Klein, JD; Price, SR; Sands, JM; Smith, TD, 2008) |
| " Ang II receptor type 1 blocker candesartan or ACE inhibitor captopril markedly attenuated eNOS-derived O(2)*(-) and hydrogen peroxide production while augmenting NO* bioavailability in diabetic aortas, implicating recoupling of eNOS." | 1.34 | Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. ( Cai, H; Oak, JH, 2007) |
| "Hypoxia caused by sleep apnea might be associated with an increased risk of cardiovascular events in subjects with metabolic syndrome." | 1.33 | Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. ( Furuya, E; Hayashi, T; Inamoto, S; Kitaura, Y; Matsumura, Y; Mori, T; Nakano, D; Okuda, N; Sakai, A; Sohmiya, K; Tazawa, N; Yamashita, C, 2006) |
| "Also, body weight was measured two times, at initial time (before STZ injection) and terminal (at the last day in the experiment)." | 1.33 | Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats. ( Awad, AS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 16 (61.54) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Khaled, S | 1 |
| Abdelaziz, RR | 1 |
| Suddek, GM | 1 |
| Elshaer, SL | 1 |
| Hofni, A | 1 |
| El-Moselhy, MA | 1 |
| Taye, A | 1 |
| Khalifa, MM | 1 |
| Danigo, A | 1 |
| Nasser, M | 1 |
| Bessaguet, F | 1 |
| Javellaud, J | 1 |
| Oudart, N | 1 |
| Achard, JM | 1 |
| Demiot, C | 1 |
| Chow, BS | 1 |
| Koulis, C | 1 |
| Krishnaswamy, P | 1 |
| Steckelings, UM | 1 |
| Unger, T | 1 |
| Cooper, ME | 3 |
| Jandeleit-Dahm, KA | 2 |
| Allen, TJ | 2 |
| Singh, VP | 1 |
| Le, B | 1 |
| Khode, R | 1 |
| Baker, KM | 1 |
| Kumar, R | 1 |
| Takimoto, C | 1 |
| Kumagai, H | 1 |
| Osaka, M | 1 |
| Sakata, K | 1 |
| Onami, T | 1 |
| Kamayachi, T | 1 |
| Iigaya, K | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Itoh, H | 1 |
| Phipps, JA | 1 |
| Clermont, AC | 1 |
| Sinha, S | 1 |
| Chilcote, TJ | 1 |
| Bursell, SE | 1 |
| Feener, EP | 1 |
| Kuwabara, T | 1 |
| Mori, K | 1 |
| Mukoyama, M | 1 |
| Kasahara, M | 1 |
| Yokoi, H | 1 |
| Saito, Y | 1 |
| Yoshioka, T | 1 |
| Ogawa, Y | 1 |
| Imamaki, H | 1 |
| Kusakabe, T | 1 |
| Ebihara, K | 1 |
| Omata, M | 1 |
| Satoh, N | 1 |
| Sugawara, A | 1 |
| Barasch, J | 1 |
| Nakao, K | 1 |
| Giunti, S | 1 |
| Calkin, AC | 1 |
| Forbes, JM | 1 |
| Thomas, MC | 2 |
| Miller, AG | 1 |
| Tan, G | 1 |
| Binger, KJ | 1 |
| Pickering, RJ | 1 |
| Nagaraj, RH | 1 |
| Wilkinson-Berka, JL | 1 |
| Kato, T | 1 |
| Yamashita, T | 1 |
| Sekiguchi, A | 1 |
| Tsuneda, T | 1 |
| Sagara, K | 1 |
| Takamura, M | 1 |
| Kaneko, S | 1 |
| Aizawa, T | 1 |
| Fu, LT | 1 |
| Takata, H | 1 |
| Takeda, Y | 1 |
| Zhu, A | 1 |
| Cheng, Y | 1 |
| Yoneda, T | 1 |
| Demura, M | 1 |
| Yagi, K | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 1 |
| Patinha, D | 1 |
| Fasching, A | 1 |
| Pinho, D | 1 |
| Albino-Teixeira, A | 1 |
| Morato, M | 1 |
| Palm, F | 1 |
| Tallam, LS | 1 |
| Jandhyala, BS | 1 |
| Li, B | 1 |
| Yao, J | 1 |
| Kawamura, K | 1 |
| Oyanagi-Tanaka, Y | 1 |
| Hoshiyama, M | 1 |
| Morioka, T | 1 |
| Gejyo, F | 1 |
| Uchiyama, M | 1 |
| Oite, T | 1 |
| Dorenkamp, M | 1 |
| Riad, A | 1 |
| Stiehl, S | 1 |
| Spillmann, F | 1 |
| Westermann, D | 1 |
| Du, J | 1 |
| Pauschinger, M | 1 |
| Noutsias, M | 1 |
| Adams, V | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Inamoto, S | 1 |
| Hayashi, T | 1 |
| Tazawa, N | 1 |
| Mori, T | 1 |
| Yamashita, C | 1 |
| Nakano, D | 1 |
| Matsumura, Y | 1 |
| Okuda, N | 1 |
| Sohmiya, K | 1 |
| Sakai, A | 1 |
| Furuya, E | 1 |
| Kitaura, Y | 1 |
| Awad, AS | 1 |
| Yaras, N | 1 |
| Bilginoglu, A | 1 |
| Vassort, G | 1 |
| Turan, B | 1 |
| Oak, JH | 1 |
| Cai, H | 1 |
| Shao, JQ | 1 |
| Iwashita, N | 1 |
| Du, H | 1 |
| Wang, YT | 1 |
| Wang, YY | 1 |
| Zhao, M | 1 |
| Wang, J | 1 |
| Watada, H | 1 |
| Kawamori, R | 1 |
| Banes-Berceli, AK | 1 |
| Ketsawatsomkron, P | 1 |
| Ogbi, S | 1 |
| Patel, B | 1 |
| Pollock, DM | 1 |
| Marrero, MB | 1 |
| Tsutsui, H | 1 |
| Matsushima, S | 1 |
| Kinugawa, S | 1 |
| Ide, T | 1 |
| Inoue, N | 1 |
| Ohta, Y | 1 |
| Yokota, T | 1 |
| Hamaguchi, S | 1 |
| Sunagawa, K | 1 |
| Huang, Z | 1 |
| Jansson, L | 1 |
| Sjöholm, A | 1 |
| Blount, MA | 1 |
| Sands, JM | 1 |
| Kent, KJ | 1 |
| Smith, TD | 1 |
| Price, SR | 1 |
| Klein, JD | 1 |
| Kato, S | 1 |
| Luyckx, VA | 1 |
| Ots, M | 1 |
| Lee, KW | 1 |
| Ziai, F | 1 |
| Troy, JL | 1 |
| Brenner, BM | 1 |
| MacKenzie, HS | 1 |
26 other studies available for candesartan and Alloxan Diabetes
| Article | Year |
|---|---|
Candesartan protects against unilateral peripheral limb ischemia in type-2 diabetic rats: Possible contribution of PI3K-Akt-eNOS-VEGF angiogenic signaling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Ischemia; Neovascularization, P | 2023 |
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabete | 2014 |
Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Diabetes Melli | 2015 |
The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles | 2016 |
Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis.
Topics: Amides; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2008 |
Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2008 |
Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2009 |
Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Albumins; Angiotensin II Type 1 Receptor Blockers; Animal | 2009 |
The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compou | 2010 |
Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2010 |
Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Com | 2011 |
Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2012 |
Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independently of adenosine type I receptors.
Topics: Adenosine A1 Receptor Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; | 2013 |
Influence of plasma insulin levels on antinatriuretic and vasoconstrictor actions of angiotensin-II.
Topics: Angiotensin II; Animals; Anti-Bacterial Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2003 |
Real-time observation of glomerular hemodynamic changes in diabetic rats: effects of insulin and ARB.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Bl | 2004 |
Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2005 |
Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2006 |
Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Caffeine; Calc | 2007 |
Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Captopril; Dia | 2007 |
Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2007 |
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrasentan; Benzi | 2007 |
Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Blo | 2007 |
Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2008 |
Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporin 2; Benzimidazoles; Biphenyl Compounds; D | 2008 |
Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; | 1999 |